Neural Regeneration Research ›› 2024, Vol. 19 ›› Issue (7): 1446-1453.doi: 10.4103/1673-5374.386400

Previous Articles     Next Articles

Neuronal conversion from glia to replenish the lost neurons

Shiyu Liang1, 2, #, Jing Zhou3, #, Xiaolin Yu1, Shuai Lu1, Ruitian Liu1, *   

  1. 1National Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, China; 2School of Chemical Engineering, University of Chinese Academy of Sciences, Beijing, China; 3Department of Geriatric Rehabilitation, Beijing Rehabilitation Hospital, Capital Medical University, Beijing, China
  • Online:2024-07-15 Published:2023-11-28
  • Contact: Ruitian Liu, PhD, rtliu@ipe.ac.cn.
  • Supported by:
    This work was supported by the Strategic Priority Research Program of the Chinese Academy of Sciences, No. XDB39050600 (to RL); the National Natural Science Foundation of China, No. 81971610 (to RL); Beijing Rehabilitation Hospital Introduction of Talent Research Start-up Fund, No. 2021R-008 (to JZ).

Abstract: Neuronal injury, aging, and cerebrovascular and neurodegenerative diseases such as cerebral infarction, Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia, amyotrophic lateral sclerosis, and Huntington’s disease are characterized by significant neuronal loss. Unfortunately, the neurons of most mammals including humans do not possess the ability to self-regenerate. Replenishment of lost neurons becomes an appealing therapeutic strategy to reverse the disease phenotype. Transplantation of pluripotent neural stem cells can supplement the missing neurons in the brain, but it carries the risk of causing gene mutation, tumorigenesis, severe inflammation, and obstructive hydrocephalus induced by brain edema. Conversion of neural or non-neural lineage cells into functional neurons is a promising strategy for the diseases involving neuron loss, which may overcome the above-mentioned disadvantages of neural stem cell therapy. Thus far, many strategies to transform astrocytes, fibroblasts, microglia, Müller glia, NG2 cells, and other glial cells to mature and functional neurons, or for the conversion between neuronal subtypes have been developed through the regulation of transcription factors, polypyrimidine tract binding protein 1 (PTBP1), and small chemical molecules or are based on a combination of several factors and the location in the central nervous system. However, some recent papers did not obtain expected results, and discrepancies exist. Therefore, in this review, we discuss the history of neuronal transdifferentiation, summarize the strategies for neuronal replenishment and conversion from glia, especially astrocytes, and point out that biosafety, new strategies, and the accurate origin of the truly converted neurons in vivo should be focused upon in future studies. It also arises the attention of replenishing the lost neurons from glia by gene therapies such as up-regulation of some transcription factors or down-regulation of PTBP1 or drug interference therapies. 

Key words: astrocytes, neural stem cells, neurodegenerative diseases, neuron, polypyrimidine tract binding protein 1, repair, reprogramming, small molecule, transcription factor, transdifferentiation